Delayed takeoff of the digital pathology market
First written in FY2016. 4 of 8 entries say "Materialised", first in FY2016. Latest entry: FY2022.
inspec moved to the "Worse" side of this theme in 2016.
0 other companies' latest entry also says "Dropped".
- FY2022DroppedAnnual report
「The company operates in a single segment, the semiconductor package substrate and precision substrate inspection equipment-related business, and therefore does not disclose results by segment.」
After the restructuring of the First EIE and Path Imaging businesses, no specific risk relating to the delayed takeoff of the digital pathology market was disclosed, and disclosure shifted to a single business. - FY2018WorsenedAnnual report
「However, because the above policy was announced at the end of the period, some users were observed holding back on purchases, among other factors, and the sales target was not achieved. As a result, revenue from the business was ¥30 million, down 32.7% year on year, and the segment loss was ¥152 million, compared with a segment loss of ¥84 million in the same period of the previous year.」
Although a path toward reimbursement claims for digital pathology image diagnosis had opened, purchases were held back because the announcement came at the end of the period. The sales target was not achieved, revenue fell 32.7% year on year, and the segment loss was ¥152 million. - FY2018-Q3WorsenedAnnual report
「During the third quarter cumulative consolidated period, revenue fell short of the initial plan because WSI, which digitizes pathology specimens, remained in the process of developing the legal framework needed to enable pathology testing using digital images, while the company focused on developing new products in anticipation of reimbursement coverage policies. As a result, revenue from the business was ¥16 million, down 45.0% year on year, and the segment loss was ¥108 million, compared with a segment loss of ¥59 million in the same period of the previous year.」
The market’s delayed takeoff continued while the legal framework was still under development, and revenue fell short of the initial plan. Revenue was down 45.0% year on year, while the segment loss widened from ¥59 million to ¥108 million, indicating a further deterioration in the impact. - FY2018-Q2WorsenedAnnual report
「During the second quarter cumulative consolidated period, WSI (Whole Slide Imaging), which digitizes pathology specimens, remained in the process of developing the legal framework needed to enable pathology testing using digital images. The company also focused on developing new products in anticipation of reimbursement coverage policies, causing revenue for the period to fall short of the initial plan. As a result, revenue from the business was ¥12 million, down 6.4% year on year, and the segment loss was ¥67 million, compared with a segment loss of ¥36 million in the same period of the previous year.」
The market’s delayed takeoff continued while the legal framework was still under development, and revenue fell short of the initial plan. The segment loss also widened from ¥36 million in the same period of the previous year to ¥67 million, showing the worsening impact in the figures. - FY2018-Q1MaterialisedAnnual report
「During the first quarter of the current consolidated cumulative period, revenue from WSI (Whole Slide Imaging), which converts pathological specimens into digital images, fell below the initial plan because the Company was focusing on developing new products in anticipation of legislation enabling pathology testing using digital images and the policy for insurance coverage. As a result, revenue from the business was ¥1 million and the segment loss was ¥37 million.」
With the relevant legal framework still under development, the company focused on developing new products in anticipation of reimbursement coverage. As a result, WSI revenue fell short of the initial plan, coming to ¥1 million, with a segment loss of ¥37 million. The delayed market and business takeoff is reflected in the results. - FY2017-Q2MaterialisedAnnual report
「During the first half of the current fiscal year, we worked to expand sales channels for WSI (Whole Slide Imaging, formerly known as the virtual slide system) and focused on securing orders, but the expansion of the sales market has not progressed as expected, and sales remained at a low level.」
The delayed takeoff of the WSI sales market continued. Despite efforts to expand sales channels and secure orders, revenue was ¥13 million and the segment loss was ¥36 million. - FY2017-Q1MaterialisedAnnual report
「During the first quarter of the current fiscal year, we worked to expand sales channels for WSI (Whole Slide Imaging, formerly known as the virtual slide system) and focused on securing orders, but sales remained at a low level.」
The WSI market remains slow to get off the ground. Despite efforts to expand sales channels and secure orders, the digital pathology business generated revenue of ¥8 million and a segment loss of ¥2 million. - FY2016MaterialisedAnnual report
「Results fell short of the initial plan because the domestic market for virtual slide systems used in telemedicine examinations and other applications, internationally known as WSI (Whole Slide Imaging), has not expanded as quickly as expected, while overseas expansion remained at the preparation stage.」
The Terra business fell short of the initial plan, generating revenue of ¥25 million and a segment loss of ¥5 million. The company cites the delayed market expansion and the overseas business remaining at the preparation stage as the reasons.